Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies-Reference-Cited by-同舟云学术

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Published:2012-12 Issue:18 Volume:48 Page:3319-3327
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mahadevan D.,Chiorean E.G.,Harris W.B.,Von Hoff D.D.,Stejskal-Barnett A.,Qi W.,Anthony S.P.,Younger A.E.,Rensvold D.M.,Cordova F.,Shelton C.F.,Becker M.D.,Garlich J.R.,Durden D.L.,Ramanathan R.K.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. PI3K pathway alterations in cancer: variations on a theme;Yuan;Oncogene,2008

2. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu;Nat Rev Drug Discovery,2009

3. Targeting PI3K signaling in cancer: opportunities, challenges and limitations;Engelman;Nat Rev Cancer,2009

4. The PI3K pathway as drug target in human cancer;Courtney;J Clin Oncol,2010

5. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation;Chan;Annu Rev Biochem,1999

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-06

2. Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma;Annals of Medicine;2024-03-15

3. Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?;Expert Opinion on Therapeutic Targets;2024-03-03

4. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer;International Journal of Molecular Sciences;2024-03-01

5. Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer;Current Cancer Drug Targets;2024-02-21